# Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study

> **NCT04524884** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 10 (estimated)

## Conditions studied

- Thyroid Cancer

## Interventions

- **DRUG:** Surufatinib
- **DRUG:** Toripalimab

## Key facts

- **NCT ID:** NCT04524884
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-10-01
- **Primary completion:** 2022-04-30
- **Final completion:** 2022-09-30
- **Target enrollment:** 10 (ESTIMATED)
- **Last updated:** 2020-08-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04524884

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04524884, "Toripalimab Combined With Surufatinib for Locally Advanced Thyroid Cancer: a Phase II Study". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT04524884. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*